# A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

> **NCT01986933** · PHASE2 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 264 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** nemolizumab (CIM331)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01986933
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-04
- **Final completion:** 2016-06
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986933, "A Phase 2 Study of CIM331 for Atopic Dermatitis Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01986933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*